GENEVA--(BUSINESS WIRE)--Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today its planned participation at upcoming industry conferences for the first part of 2018, as follows:
J.P. Morgan 36th Annual Healthcare
Conference (JPM)
8 – 11 January 2018, San Francisco,
California
In conjunction with the JPM conference, Selexis will be participating in the BIO 1:1 partnering meetings.
Schedule at partnering meeting at https://www.bio.org/events/one-on-one-partnering-jpm
To schedule a meeting with the Selexis BD team during JPM outside of BIO, please visit http://selexis.com/contact/
PEPTALK 2018
8 – 12 January 2018, Hilton San Diego
Bayfront, San Diego, California
Selexis will present, sponsor and exhibit at the conference.
Selexis’ CSO, Pierre-Alain Girod, Ph.D., will present, “Using SUREscan to Survey Genetic Changes in Stable CHO Cell Lines,” on Thursday, January 11 at 11:30 a.m. PT as part of the Bioprocess Analytics tract.
FULL ABSTRACT: CHO cells are the most frequently applied host-cell system for industrial protein therapeutic manufacturing. Rapid generation of high-producing clones that don’t lose expression capability over time has been a major industry focus. Using SUREscan™ with next-generation sequencing (NGS), we can quickly analyze whole genomes of any cell line, improving traceability of research cell banks (RCBs). In contrast to other CHO published data, we will show that the SUREtechnology Platform™ generates RCBs with chromosomally stable lineages.
Visit Selexis Booth 208
Learn more about PEPTALK at http://www.chi-peptalk.com/
BIO-Europe Spring
12 – 14 March 2018, Amsterdam RAI
Convention Center, Amsterdam, The Netherlands
Selexis will participate in the partnering program and is a conference sponsor.
Schedule a partnering meeting at https://ebdgroup.knect365.com/bioeurope-spring/
Cell Line Development & Engineering
23 – 25 April
2018, Amsterdam RAI Convention Center, Amsterdam, The Netherlands
Selexis will present, sponsor and exhibit at the conference.
Selexis’ CSO, Pierre-Alain Girod, Ph.D., will be presenting. Talk title to be announced.
Visit Selexis Booth 68
Learn more about the conference at https://lifesciences.knect365.com/cell-line-congress/
14th Annual PEGS Summit
30 April
– 4 May 2018, Seaport World Trade Center, Boston, Massachusetts
Selexis will present, sponsor and exhibit and present at the conference.
Selexis’ CSO, Pierre-Alain Girod, Ph.D., will be presenting on Wednesday, May 2 at 12:25 p.m. ET as part of the Engineering Antibodies tract. Talk title to be announced.
Visit Selexis Booth 440
For more information, please visit: http://www.pegsummit.com/
2018 BIO International Convention
4 – 7 June 2018, Boston
Convention & Exhibition Center, Boston, Massachusetts
Selexis will be exhibiting at this conference and participating in the partnering program.
Visit Selexis Booth 878
Schedule a partnering meeting at http://convention.bio.org/2018/
About Selexis SA
Selexis SA is a pioneering life sciences company and a global leader in mammalian (suspension-adapted CHO-K1) cell line generation, providing unparalleled proprietary technology and the highly-specialized expertise that is necessary to translate scientific innovation into life-saving medicines for patients. Selexis’ SUREtechnology Platform™ facilitates the rapid, stable, and cost-effective production of virtually any recombinant protein and provides seamless integration of the bioproduction continuum, spanning discovery to commercialization. With more than 100 partners worldwide, 85 drug products in clinical development and three commercial products utilizing Selexis-generated cell lines, the Company has a history of empowering scientists and biopharmaceutical companies around the world to realize the full potential of their research. More information is available at www.selexis.com.
|
FOR MORE INFORMATION |
|||||
| - Web | |||||
